J

Johnson & Johnson

Makes prescription drugs and medical devices

Global Platform Engineer - Sales CPQ PRO AMP

Full-TimePosted on 9/18/2026Deadline 10/17/26
$137k - $236.3k
Expert
Raritan, NJ, USA
Remote
DevOps & InfrastructurePlatform Engineering

About the job

Requirements
  • At least 10 years of software engineering experience delivering enterprise-scale digital products, platforms, or distributed systems.
  • At least 7 years as a lead architect, principal engineer, platform engineer, or engineering leader accountable for architecture and technical strategy.
  • Demonstrated experience leading a large-scale platform modernization or transformation across multiple teams, products, regions, or business units.
  • Deep expertise in Microsoft Dynamics 365 architecture, extensibility, integration, data models, security, release management, and platform operations.
  • Experience with Microsoft Azure services and integrations across Microsoft 365, including Teams, Outlook, Copilot, and Copilot Studio.
  • Proven experience designing reusable APIs, services, frameworks, SDKs, engineering patterns, or internal developer capabilities rather than only standalone applications.
  • Hands-on understanding of modern engineering practices and tooling, including Git, CI/CD, infrastructure as code, containers, Kubernetes, automated testing, and platform observability.
  • Experience designing or implementing production AI solutions using capabilities such as LLM integration, agent orchestration, RAG, tool calling, context engineering, evaluation, observability, security, and governance.
  • Experience operating in a highly regulated, security-conscious, or otherwise complex enterprise environment.
  • Strong understanding of commercial business processes such as sales, pricing, quoting, contracting, customer engagement, or professional relations.
  • Demonstrated ability to lead through influence across product, engineering, enterprise architecture, security, vendors, and senior stakeholders.
  • Experience providing technical leadership to employees, contractors, delivery partners, or federated engineering teams.
Responsibilities
  • Define and evolve the target architecture and multi-year technical roadmap for the Butterfly CXM platform, with direct accountability for Sales, CPQ, and PR&O.
  • Establish platform boundaries, extension patterns, data flows, integration contracts, identity and access patterns, and non-functional requirements.
  • Ensure architecture decisions support global scale, security, privacy, regulatory requirements, reliability, performance, maintainability, and controlled regional variation.
  • Make technology trade-offs that balance immediate release needs with long-term platform health.
  • Define and lead development of reusable APIs, services, integration patterns, frameworks, SDKs, components, and developer tooling used across CxM product pods.
  • Establish governed patterns for Microsoft Dynamics configuration, customization, integration, data access, testing, release management, and environment management.
  • Create and maintain a catalog of approved platform services, reusable business capabilities, technical patterns, and implementation guidance.
  • Improve developer productivity and delivery quality through automation, standardization, observability, and modern software engineering practices.
  • Define the technical approach for embedding AI and agent-based capabilities into priority commercial workflows across Sales, CPQ, and PR&O.
  • Lead reusable patterns for agent orchestration, tool calling, skills, context management, retrieval-augmented generation, human oversight, evaluation, and lifecycle management.
  • Partner with enterprise AI platform teams to implement governed execution, security controls, observability, discoverability, and production operations.
  • Advance interoperability patterns, including Model Context Protocol and agent-to-agent integration, where appropriate, approved, and valuable.
  • Own CXM platform engineering standards and technical guardrails while aligning with enterprise architecture, cloud, cybersecurity, privacy, data, and AI policies.
  • Provide technical direction and quality oversight across internal engineers, product pods, contractors, systems integrators, and strategic technology partners.
  • Lead architecture reviews, resolve cross-team technical dependencies, and intervene early when delivery choices create platform risk or unnecessary duplication.
  • Coach engineers and technical leads, strengthen engineering capability, and create a culture of accountability, reuse, documentation, and continuous improvement.
  • Communicate architecture decisions, risks, trade-offs, and investment needs clearly to product, business, technology, and executive stakeholders.
Desired Qualifications
  • Experience in MedTech, pharmaceutical, healthcare, or another regulated industry.
  • Experience integrating Microsoft-based business platforms with enterprise services operating across Azure and AWS environments, including API, event-driven, data, identity, security, and observability services.
  • Experience building enterprise agent platforms, internal developer platforms, reusable SDKs, framework libraries, or shared engineering services.
  • Experience designing global platforms that support controlled local or regional variation.
  • Experience managing systems integrators and strategic technology partners in complex delivery environments.
  • Experience leading engineering capability building or organizational transformation.
  • For internal candidates, working knowledge of XENA engineering standards, accelerators, AI-enabled SDLC practices, enterprise architecture standards, deployment frameworks, and CI/CD governance; external candidates should demonstrate experience adopting comparable enterprise engineering frameworks and the ability to rapidly learn J&J standards.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

INACTIVE